%PDF-1.4
%
32 0 obj
<>
endobj
28 0 obj
<>
endobj
84 0 obj
<>stream
Acrobat Distiller 5.0 for Macintosh
2003-02-05T20:04:57Z
2024-03-28T05:45:53-07:00
2024-03-28T05:45:53-07:00
QuarkXPress. 4.11: AdobePS 8.6 (219)
application/pdf
Heather
2002-318.MARCH
uuid:110b4f33-1dd2-11b2-0a00-db09278d5b00
uuid:110b4f37-1dd2-11b2-0a00-1e0000000000
endstream
endobj
17 0 obj
<>
endobj
18 0 obj
<>
endobj
33 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
102 0 obj
[106 0 R]
endobj
103 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
427 777 130 -27 re
f
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:3)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(484)Tj
ET
0 0 0 0 scn
/GS0 gs
109.25 59.1 396.47 -10.84 re
f
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 scn
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.0842 Tw 10 0 0 10 54 713.1616 Tm
(polymorphism for sulfa metabolism could be similar as an)Tj
0.15829 Tw 0 -1.2 TD
(explanation to high incidences of sulfa reactions in the 2)Tj
0 Tw T*
(groups.)Tj
0.0184 Tc 0.35651 Tw 1.2 -1.2 Td
[(Studying a family heterozygous to C2 deficiency)64.7 (,)]TJ
-0.00011 Tc 0 Tw -1.2 -1.2 Td
(McCarty )Tj
/T1_0 1 Tf
0.0815 Tw 3.8857 0 Td
(et al)Tj
/T1_1 1 Tf
2.1625 0 Td
(found the index case had SLE, but a family)Tj
0.0063 Tw -6.0482 -1.2 Td
(member had joint pains while taking sulfa drugs and a posi-)Tj
0.0305 Tw T*
(tive LE preparation)Tj
0 Tc 0 Tw 6.5 0 0 6.5 132.3494 644.4615 Tm
(20)Tj
-0.00011 Tc 0.0305 Tw 10 0 0 10 138.8493 641.1616 Tm
(. She did not have SLE. C2 deficiency)Tj
0.283 Tw -8.4849 -1.2 Td
(could be associated with increased problems with sulfa)Tj
0.0061 Tw T*
(drugs, but from the evidence of one case report we can only)Tj
0.13651 Tw T*
(speculate. Our subjects did not complain of arthralgias as)Tj
0.1147 Tw T*
(ADR, but had reasons for their joint pains related to their)Tj
0.02499 Tw T*
(SLE or inflammatory arthritis.)Tj
-0.08 Tc 0 Tw 1.2 -1.2 Td
[(We)-79.9 ( )]TJ
-0.00011 Tc 0.0905 Tw 1.6483 0 Td
(conclude that most adverse drug reactions were not)Tj
0.1922 Tw -2.8483 -1.2 Td
(increased in patients with SLE, except rashes from sulfa)Tj
0.17599 Tw T*
(antibiotics or sulfamethoxazole-trimethoprim, which were)Tj
0.00819 Tw T*
(increased by 4-fold compared to other subjects with inflam-)Tj
0.0789 Tw T*
[(matory arthritis. )17.7 (The reason for this is not clear)39.7 (, and could)]TJ
0.2789 Tw T*
(be due to an SLE phenotype or other pharmacogenetic)Tj
0.1664 Tw T*
[(dif)17.7 (ferences between individuals with SLE and those with)]TJ
0.0369 Tw T*
(inflammatory arthritis. In addition, subjects with a personal)Tj
0.1823 Tw T*
[(or family history of atopy and/or environmental aller)17.7 (gies)]TJ
0.0199 Tc 0.36591 Tw T*
[(were more likely to have )55 (ADR than those without.)]TJ
-0.00011 Tc 0.3701 Tw T*
(Physicians should take a detailed personal and family)Tj
0.2045 Tw T*
[(history of aller)17.7 (gies while treating patients with SLE and)]TJ
-0.0094 Tw T*
[(inflammatory arthritis. )17.8 (When prescribing sulfa antibiotics to)]TJ
0.00349 Tw T*
(patients with SLE, there should be an index of suspicion for)Tj
0.02499 Tw T*
(cutaneous reactions.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 367.1616 Tm
[(1.)-875.1 (Becker LC. )54.8 (Aller)17.7 (gy in systemic lupus erythematosus. Johns)]TJ
0 Tc 1.675 -1.25 Td
(Hopkins Med J 1973;133:38-44.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (V)128.9 (on Maur K, )17.7 (T)35 (urk )54.8 (A, Stevens MB, )54.8 (Adkinson NF)79.7 (, Lichtenstein LM.)]TJ
1.675 -1.25 Td
(Penicillin hypersensitivity in systemic lupus erythematosus. Int)Tj
-0.0298 Tw 0 -1.25 TD
[(Arch Aller)17.7 (gy Appl )-54.8 (Immunol )-54.8 (1975;49:428-33.)]TJ
0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Petri M, )54.8 (Allbritton J. )54.8 (Antibiotic aller)17.7 (gy in systemic lupus )]TJ
1.675 -1.25 Td
[(erythematosus: )54.8 (A)-220.1 (case-control study)64.8 (. J Rheumatol 1992;19:265-9.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
1.675 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
31.325 58.421 Td
[(6.)-875.1 (Finch )17.7 (WR, Strottman MP)110.7 (. )54.8 (Acute adverse reactions to ibuprofen in)]TJ
1.675 -1.25 Td
[(systemic lupus erythematosus. JAMA)-220.2 (1979;241:2616-8.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Crof)17.7 (ford LJ, Oates JC, McCune )17.7 (WJ, et al. )17.7 (Thrombosis in patients)]TJ
1.675 -1.25 Td
(with connective tissue diseases treated with specific )Tj
T*
[(cyclooxygenase 2 inhibitors. )54.8 (A)-220.1 (report of four cases. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2000;43:1891-6.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Fye KH, Crowley E, Ber)17.7 (ger )17.7 (TG, LeBoit PE, Connolly MK.)]TJ
1.675 -1.25 Td
[(Celecoxib-induced Sweet\325)54.8 (s syndrome. J )54.8 (Am )54.8 (Acad Dermatol)]TJ
0 Tc 0 Tw T*
(2001;45:300-2.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Chassagne P)110.7 (, Mejjad O, Gourmelen O, Moore N, Le Loet X,)]TJ
1.675 -1.25 Td
[(Deshayes P)110.8 (. Exacerbation of systemic lupus erythematosus during)]TJ
T*
(human parvovirus B19 infection. Br J Rheumatol 1993;32:158-9.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Drayer DE, Reidenber)17.7 (g MM. Clinical consequences of )]TJ
2.175 -1.25 Td
[(polymorphic acetylation of basic drugs. Clin Pharmacol )17.7 (Ther)]TJ
0 Tc 0 Tw T*
(1977;22:251-8.)Tj
-0.0369 Tc -2.1381 -1.25 Td
[(11)-36.9 (.)]TJ
-0.00011 Tc 0.02499 Tw 2.0881 0 Td
[(Baer )54.8 (AN, )17.7 (W)79.9 (oosley RL, Pincus )17.7 (T)74 (. Further evidence for the lack of)]TJ
0.05 -1.25 Td
(association between acetylator phenotype and systemic lupus)Tj
T*
[(erythematosus. )54.8 (Arthritis Rheum 1986;29:508-14.)]TJ
0 Tc -2.175 -1.25 Td
[(12.)-875 (Kumana CR, Chan MM, )17.7 (W)80 (ong KL, )17.7 (W)80 (ong R)54.9 (W)91.9 (, Kou M, Lauder IJ.)]TJ
-0.00011 Tc 2.175 -1.25 Td
(Lack of association between slow acetylator status and spontaneous)Tj
T*
[(lupus erythematosus. Clin Pharmacol )17.7 (Ther 1990;48:208-13.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Ong ML, Mant )17.7 (TG, )17.7 (V)110.8 (eerapen K, et al. )17.7 (The lack of relationship)]TJ
2.175 -1.25 Td
(between acetylator phenotype and idiopathic systemic lupus )Tj
T*
[(erythematosus in a Southeast )54.8 (Asian population: a study of Indians,)]TJ
T*
(Malays and Malaysian Chinese. Br J Rheumatol 1990;29:462-4.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Escalante )54.8 (A, Stimmler MM. )17.7 (T)35 (rimethoprim-sulfamethoxazole)]TJ
2.175 -1.25 Td
(induced meningitis in systemic lupus erythematosus. J Rheumatol)Tj
0 Tc 0 Tw T*
(1992;19:800-2.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Carlson J, )17.7 (W)39.8 (iholm BE. )17.7 (T)35 (rimethoprim associated aseptic meningitis.)]TJ
2.175 -1.25 Td
(Scand J Infect Dis 1987;19:687-91.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Antonen J, Saha H, Hulkkonen J, Lumio J, Pasternack )54.8 (A, Hurme)]TJ
2.175 -1.25 Td
(M. Increased in vitro production of interleukin 6 in response to)Tj
T*
(trimethoprim among persons with trimethoprim induced systemic)Tj
T*
(adverse reactions. J Rheumatol 2000;27:2585-90.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (River )36.8 (Y)128.9 (,)-0.1 ( )54.8 (A)74 (verbuch-Heller L, )17.7 (W)79.9 (einber)17.7 (ger M, et al. )54.8 (Antibiotic)]TJ
2.175 -1.25 Td
[(induced meningitis. J Neurol Neurosur)17.7 (g Psychiatry 1994;57:705-8.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Biosca M, De La Figuera M, Garcia-Bragado F)79.7 (, Sampol G. )54.8 (Aseptic)]TJ
2.175 -1.25 Td
(meningitis due to trimethoprim-sulfamethoxazole. J Neurol)Tj
T*
[(Neurosur)17.7 (g Psychiatry 1986;49:332-3.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (R)39.7 (yan C, Madalon M, )17.7 (W)79.9 (ortham DW)91.7 (, Graziano FM. )]TJ
2.175 -1.25 Td
[(Sulfa hypersensitivity in patients with HIV)-257.3 (infection: onset,)]TJ
T*
[(treatment, critical review of the literature. )17.7 (WMJ 1998;97:23-7.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (McCarty DJ, )17.7 (T)69.9 (an EM, Zvaifler NJ, Koethe S, Duquesnoy RJ.)]TJ
2.175 -1.25 Td
[(Serologic studies in a family with heterozygous C2 deficiency)64.8 (. )54.8 (Am)]TJ
0 Tc T*
(J Med 1981;71:945-8.)Tj
ET
0 0 0 0 scn
434 770 124 -25 re
f
BT
0 0 0 1 scn
/T1_3 1 Tf
-0.00011 Tc 0 Tw 20.37 0 0 21 461.9631 753.6089 Tm
(2002-318-5)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
36 0 obj
<>
endobj
45 0 obj
<>
endobj
13 0 obj
<>
endobj
37 0 obj
<>
endobj
73 0 obj
<>
endobj
89 0 obj
<>
endobj
39 0 obj
<>
endobj
41 0 obj
<>
endobj
38 0 obj
<>stream
HTMo0
;i%ąjRvaH#Dgci~mQxOt`!zN_Em^p